## Appendix 1

## Association between Serotonin transporter promoter polymorphisms and response to treatment

Table of contents

	Pages
Methods	2
Results	2
Table S1	3

## Methods

DNA was extracted from 200 µl of citrated blood using the QIAamp DNA Blood Mini Kit (Qiagen Cat. No. 51106) and then genotyped. PCR included DMSO and used the primer sequences FORWARD 5'GGCGTTGCCGCTCTGAATGC3' and REVERSE 5'GAGGGACTGAGCTGGACAACCAC3'. We used biotaq (bioline) 54°C and 35 cycles. PCR products were run on a 2% agarose gel to distinguish the difference in band sizes of 484/528bp. A band of 528bp indicated *I/l*, 484 and 528bp *I/s* and 484bp only indicated *ss* genotype. The alleles were in Hardy Weinberg equilibrium.

The differences across the groups were tested with ANOVA.

## Results

Genotype data are available for 96 (97%) of ITT patients. Thirty (30.3%) patients had *II* genotype, 25 (25.3%) had *sI* genotype and 41 (41.4%) had *ss* genotype. No statistically significant differences across the groups were found for primary or most secondary outcomes (Table S1). However our data indicate that *sI* genotype patients may react more favorably to Ondansetron (bigger improvement in stool form and bigger increase in transit time) compared to II genotype patients though the differences never reached 5% statistical significance (data on request).

Primary and secondary efficacy	11	sl	55
parameters			
(differences between			
Ondansetron placebo periods)			
Stool form	-0.7 (-1.2, -0.3)**	-1.2 (-1.6, -1.8)***	-0.5 (-1.0, 0.0)
p-value		0.069	
Days with pain	-0.1 (-0.8, 0.7)	-0.4 (-1.1, 0.2)	-0.3 (-1.2, 0.5)
p-value		0.741	
Days with urgency	-0.7 (-1.4, 0.1)	-1.2 (-1.9, -0.5)**	-1.3 (-2.3, -0.5)**
p-value		0.467	
Days with bloating	-0.6 (-1.3, 0.2)	-0.5 (-1.1, 0.2)	-1.1 (-2.0, -0.3)**
p-value		0.421	
Pain score	-0.07 (0.29, 0.15)	-0.12 (-0.31, 0.07)	-0.09 (-0.34, 0.15)
p-value		0.943	
Urgency score	-0.20 (-0.44, 0.04)	-0.39 (-0.59, -0.19)***	-0.35 (-0.61, -0.09)**
p-value		0.472	
Bloating score	-0.06 (-0.31, 0.19)	-0.07 (-0.28, 0.15)	-0.32 (-0.60, -0.05)*
p-value		0.280	
Stool frequency, reduction %	4 (16, -8)	18 (28, 8)**	7 (20, -6)
p-value		0.177	
Whole gut transit time increase <sup>3</sup> ,	11.8 (4.5, 19.1)**	17.1 (10.6, 23.7)***	4.9(-3.0, 12.8)
hours p-value		0.066	

Table S1. Mean differences (95% confidence intervals) between Ondansetron and placebo periods for various genotypes<sup>1,2</sup>

<sup>1</sup> exact p-values shown for the overall difference across the genotypes

<sup>2</sup>Statistical significance indicated for tests of the mean differences against 0.

<sup>3</sup>The data are available for 87 patients

\*p<0.05, \*\*p<0.01, \*\*\*p<0.001